How much funding has Evom AI raised?

Evom AI has raised $1.1M+ in total funding. Their latest funding round was Seed. Key investors include Kklim Ventures (끌림벤처스), Ministry of SMEs and Startups (TIPS).

Where is Evom AI headquartered?

Evom AI is headquartered in Seoul, South Korea. The company has a team of 6-15 people.

What does Evom AI do?

Evom AI operates in the AI in Healthcare sector. A healthcare AI startup developing a multimodal diagnostic and predictive platform for cardiovascular diseases by fusing electrocardiogram (ECG) and echocardiography (Echo) data. Enhances diagnostic precision and enables proactive heart disease management by integrating electrical (ECG) and structural (Echocardiogram) heart signals into a single predictive model.

When was Evom AI founded?

Evom AI was founded in 2025. It is based in Seoul, South Korea.

How much funding has Evom AI raised?

Evom AI has raised $1.1M+ in total funding. Key investors include Kklim Ventures (끌림벤처스), Ministry of SMEs and Startups (TIPS).

Who is the CEO of Evom AI?

Hyeonseob Nam is the CEO of Evom AI. The company was founded in 2025.

Where is Evom AI located?

Evom AI is headquartered in Seoul, South Korea.

What funding stage is Evom AI at?

Evom AI is currently at the Early Stage stage.

How many employees does Evom AI have?

Evom AI has approximately 6-15 employees.

Evom AI

Category: AI in Healthcare

A healthcare AI startup developing a multimodal diagnostic and predictive platform for cardiovascular diseases by fusing electrocardiogram (ECG) and echocardiography (Echo) data. Evom AI was founded in 2025. The company is led by Hyeonseob Nam. Based in Seoul, South Korea. Team size: 6-15. Total funding raised: $1.1M+. Latest round: Seed. Key investors include Kklim Ventures (끌림벤처스), Ministry of SMEs and Startups (TIPS).

Founded: 2025
Headquarters: Seoul, South Korea
Team size: 6-15
Total funding: $1.1M+

Value proposition

Enhances diagnostic precision and enables proactive heart disease management by integrating electrical (ECG) and structural (Echocardiogram) heart signals into a single predictive model.

Products and solutions

ECG AI Solution: Analyzes minute waveform signals to support rapid clinical judgment., Echocardiogram AI Solution: Automatically measures dozens of heart parameters and assists in functional evaluation., Multimodal Risk Prediction Engine: A predictive model that fuses Echo and ECG data to identify severe heart disease risks in advance.

Unique value

Evom AI focuses on 'Multimodal AI,' which is unique because it analyzes heart health from both electrical (ECG) and mechanical/structural (Echo) perspectives simultaneously, whereas most competitors focus on only one modality.

Target customer

Tertiary hospitals, cardiology clinics, and diagnostic centers requiring advanced cardiac screening tools.

Industries served

Healthcare AI, Medical Diagnostics, Cardiology, Digital Health

Technology advantage

The founding team consists of top-tier medical AI experts from Lunit and Mediwhale, bringing deep experience in FDA/CE-cleared AI software development and large-scale clinical validation.

How they differentiate

Evom AI utilizes a 'Multimodal AI' approach that integrates both electrical heart signals (ECG) and structural heart data (Echocardiography). This contrasts with most competitors who focus on a single modality, allowing Evom AI to provide a more holistic and proactive diagnostic tool for cardiovascular disease.

Main competitors

VUNO (뷰노), Medical AI (메디컬에이아이), DeepCardio (딥카디오), Ultromics

Key partnerships

Kklim Ventures (Seed Investor), Ministry of SMEs and Startups (Deep Tech TIPS Program partner), Leading Korean university hospitals (for ongoing clinical data collection and validation), Naver D2SF (Accelerator partner, joined August 2025)

Notable customers

Seoul National University Hospital (Clinical Data Partner), Leading South Korean University Hospitals (Validation stage)

Major milestones

Founded in early 2025 by a team of medical AI veterans from Lunit, Mediwhale, and SNU/MIT, Secured early Seed funding from Kklim Ventures in September 2025, Selected for the 1.5 billion KRW (approx. $1.1M) 'Deep Tech TIPS' program in December 2025, Evom FastEcho received MFDS digital medical device manufacturing approval in March 2026, Passed first KGMP audit for digital medical devices in May 2026, Secured Seed Bridge funding from Kklim Ventures and existing investors in June 2026

Growth metrics

Rapidly transitioned from founding (2024) to the prestigious 3-year Deep Tech TIPS program within a few months.

Market positioning

Deep-tech healthcare AI specialist focused on high-precision cardiovascular diagnostics.

Geographic focus

South Korea (Tertiary University Hospitals), with long-term targets in North America and Global markets.

Patents and IP

Proprietary AI algorithms currently under development; no specific patent registration numbers have been publicly disclosed as of the latest update.

About Hyeonseob Nam

Hyeonseob Nam is a seasoned medical AI expert with a background in both top-tier tech firms and specialized healthcare startups. He previously served as the Co-founder and CTO of Mediwhale, where he led AI R&D for retinal-based cardiovascular disease prediction. His career also includes roles as an AI Researcher at Lunit, specializing in medical computer vision, and as an AI Researcher at NAVER. He holds both a B.S. and M.S. in Computer Science from POSTECH and has published research in prestigious journals such as The Lancet Digital Health and JAMA, as well as top AI conferences including CVPR and NeurIPS.

Latest news about Evom AI

More AI in Healthcare companies

Official website: https://evom.ai/